[Primary hyperlipoproteinemia Type I in the neonatal period]

Related Experiment Video

Updated: Oct 28, 2026

Isolation of Neonatal Extrahepatic Cholangiocytes
07:54

Isolation of Neonatal Extrahepatic Cholangiocytes

Published on: June 5, 2014

B Schlüter1, E Trowitzsch, W Andler

  • 1Vestische Kinderklinik Datteln.

Klinische Padiatrie
|September 1, 1990
PubMed

Insights

A rare case of primary hyperlipoproteinemia type I in an infant was diagnosed by excluding other diseases and confirmed by absent lipoprotein lipase activity. A low-fat diet with medium-chain triglycerides significantly reduced triglyceride levels.

Area of Science:

  • Biochemistry
  • Pediatrics
  • Genetics

Background:

  • Inborn errors of lipid metabolism are rare in newborns.
  • Hyperlipoproteinemia in infancy has limited reported cases.
  • This study details a unique case of primary hyperlipoproteinemia type I in a neonate.

Purpose of the Study:

  • To diagnose and manage a rare case of hyperlipoproteinemia in a newborn.
  • To investigate the genetic basis and metabolic characteristics of the condition.
  • To evaluate the efficacy of a specialized diet in managing severe hypertriglyceridemia.

Main Methods:

  • Diagnosis by exclusion of other diseases and blood lipid analysis.
  • Assessment of lipoprotein lipase activity in postheparin plasma.
  • Monitoring growth parameters and response to a low-fat, high-medium-chain triglyceride diet.

Main Results:

  • Primary hyperlipoproteinemia type I was diagnosed in a 6-day-old infant with milky blood serum.
  • Lipoprotein lipase deficiency was confirmed, with parents identified as heterozygotes.
  • Dietary intervention significantly reduced extremely high serum triglyceride levels from 3674 mg/dl to 214-711 mg/dl.

Conclusions:

  • Early diagnosis and dietary management are crucial for managing primary hyperlipoproteinemia type I in infants.
  • The case highlights the importance of assessing lipoprotein lipase activity in suspected lipid metabolism disorders.
  • Despite successful triglyceride reduction, the infant succumbed to a pulmonary infection at 8 months, underscoring potential complications.

More Related Videos

Long-Term Catheterization of the Intestinal Lymph Trunk and Collection of Lymph in Neonatal Pigs06:25

Long-Term Catheterization of the Intestinal Lymph Trunk and Collection of Lymph in Neonatal Pigs

Published on: March 5, 2016

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

Related Concept Videos

Lipid Digestion01:16

Lipid Digestion

Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...